Top Stories
L&T Partners with PS Technology to Revolutionise Railways
6 mins read. August 2, 2024 at 12:45 PM
Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr
4 mins read. August 2, 2024 at 12:41 PM
Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr
4 mins read. August 2, 2024 at 12:36 PM

USFDA Inspection Of Granules' Visakhapatnam Unit Concludes With Zero Observations
Granules India’s active pharmaceutical ingredients (API) manufacturing facility in Visakhapatnam, Andhra Pradesh, has completed a U.S. Food and Drug Administration (U.S. FDA) inspection, the company said on Friday.
The Unit IV facility located in Visakhapatnam has successfully completed the U.S. FDA’s pre-approval inspection and GMP audit from June 26-30 with zero [Form 483] observations, the company said.
It also said in the filing that its facility at Jeedimetla (Hyderabad) also completed the US FDA’s surveillance inspection.
From June 26, 2023, through June 30, 2023, there was an audit. The company stated in an exchange filing that the Unit IV plant in Visakhapatnam produces active medicinal ingredients.
Source: Media reports
Related News

L&T Partners with PS Technology to Revolutionise Railways
6 mins read. August 2, 2024 at 12:45 PM

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr
4 mins read. August 2, 2024 at 12:41 PM

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr
4 mins read. August 2, 2024 at 12:36 PM

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr
4 mins read. August 2, 2024 at 12:33 PM
Download app
Access BlinkX
everywhere
across device
